About US

Antigen Discovery Inc   provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes. ADI’s powerful proteome microarray approach significantly decreases the time and cost required to perform proteome-wide antigen screening by eliminating time consuming steps in traditional cloning, protein expression and screening methodologies. ADI’s flexible and robust microarray platform facilitates the discovery of diagnostic biomarkers, vaccine candidates, as well as therapeutic antibody discovery and target validation.

Antigen Discovery’s customers and partners include NIH, NIAID, pharmaceutical and biotechnology companies, universities, medical centers, as well as world-wide consortiums working in the areas of infectious disease and vaccine development.